What changed: Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)
Every dated change on the records linked to Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 1
2020 · 1
2018 · 5
- 2018GuidelineAdvanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: After EDP-M
Gemcitabine with capecitabine; cabozantinib; pembrolizumab, especially for mismatch-repair-deficient tumours; streptozocin-mitotane; clinical trials.
- 2018GuidelineAdvanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: All patients
Mitotane from diagnosis with glucocorticoid replacement; adrenal enzyme inhibitors (metyrapone, osilodrostat, ketoconazole) for cortisol excess; thromboprophylaxis and infection vigilance.
- 2018GuidelineAdvanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: High-burden or progressive disease, first line
Etoposide, doxorubicin and cisplatin with mitotane (EDP-M, FIRM-ACT).
- 2018GuidelineAdvanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: Low-burden, indolent disease
Mitotane alone, with resection, thermal ablation or stereotactic radiotherapy of limited metastases.
- 2018GuidelineAdvanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)Guideline ESE/ENSAT guideline on adrenocortical carcinoma 2018: Trials
Relacorilant with checkpoint inhibition for cortisol-secreting tumours; cabozantinib with immunotherapy; radiolabelled CYP11B tracers.